Dendritic cells, inflammation, and breast cancer

Karolina Palucka, Lisa Coussens, Joyce O'Shaughnessy

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Solid tumors are well known for their genomic heterogeneity. Although some aspects of this derive from so-called driver mutations, it is now clear that tumor cells possess a seemingly limitless capacity to evade cell death pathway activation, maintain essential survival programming, and initiate resistance networks that block efficacy of cytotoxic and targeted therapy. Given this amazing survival capability, how then to design approaches for effective eradication of malignant cells Also present within all solid tumors is a diverse assemblage of genomically stable immune cell types. Whereas some of these possess documented activities that foster tumor progression, others possess inherent activities that when favored lead to rapid tumor cell elimination. This review focuses on aspects of dendritic cell biology in solid tumors, especially breast cancers, which point to dendritic cells as a tractable tool to exploit for immune-based therapies.

Original languageEnglish (US)
Pages (from-to)511-516
Number of pages6
JournalCancer Journal (United States)
Volume19
Issue number6
DOIs
StatePublished - Nov 2013

Fingerprint

Dendritic Cells
Breast Neoplasms
Inflammation
Neoplasms
Cell Biology
Cell Death
Mutation
Therapeutics

Keywords

  • h
  • Cancer
  • Dendritic Cells
  • Immunogenic Cell Death
  • Inflammation

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Dendritic cells, inflammation, and breast cancer. / Palucka, Karolina; Coussens, Lisa; O'Shaughnessy, Joyce.

In: Cancer Journal (United States), Vol. 19, No. 6, 11.2013, p. 511-516.

Research output: Contribution to journalArticle

Palucka, Karolina ; Coussens, Lisa ; O'Shaughnessy, Joyce. / Dendritic cells, inflammation, and breast cancer. In: Cancer Journal (United States). 2013 ; Vol. 19, No. 6. pp. 511-516.
@article{258187b1d6a04930922120dc70863626,
title = "Dendritic cells, inflammation, and breast cancer",
abstract = "Solid tumors are well known for their genomic heterogeneity. Although some aspects of this derive from so-called driver mutations, it is now clear that tumor cells possess a seemingly limitless capacity to evade cell death pathway activation, maintain essential survival programming, and initiate resistance networks that block efficacy of cytotoxic and targeted therapy. Given this amazing survival capability, how then to design approaches for effective eradication of malignant cells Also present within all solid tumors is a diverse assemblage of genomically stable immune cell types. Whereas some of these possess documented activities that foster tumor progression, others possess inherent activities that when favored lead to rapid tumor cell elimination. This review focuses on aspects of dendritic cell biology in solid tumors, especially breast cancers, which point to dendritic cells as a tractable tool to exploit for immune-based therapies.",
keywords = "h, Cancer, Dendritic Cells, Immunogenic Cell Death, Inflammation",
author = "Karolina Palucka and Lisa Coussens and Joyce O'Shaughnessy",
year = "2013",
month = "11",
doi = "10.1097/PPO.0000000000000007",
language = "English (US)",
volume = "19",
pages = "511--516",
journal = "Cancer journal (Sudbury, Mass.)",
issn = "1528-9117",
publisher = "Lippincott Williams and Wilkins Ltd.",
number = "6",

}

TY - JOUR

T1 - Dendritic cells, inflammation, and breast cancer

AU - Palucka, Karolina

AU - Coussens, Lisa

AU - O'Shaughnessy, Joyce

PY - 2013/11

Y1 - 2013/11

N2 - Solid tumors are well known for their genomic heterogeneity. Although some aspects of this derive from so-called driver mutations, it is now clear that tumor cells possess a seemingly limitless capacity to evade cell death pathway activation, maintain essential survival programming, and initiate resistance networks that block efficacy of cytotoxic and targeted therapy. Given this amazing survival capability, how then to design approaches for effective eradication of malignant cells Also present within all solid tumors is a diverse assemblage of genomically stable immune cell types. Whereas some of these possess documented activities that foster tumor progression, others possess inherent activities that when favored lead to rapid tumor cell elimination. This review focuses on aspects of dendritic cell biology in solid tumors, especially breast cancers, which point to dendritic cells as a tractable tool to exploit for immune-based therapies.

AB - Solid tumors are well known for their genomic heterogeneity. Although some aspects of this derive from so-called driver mutations, it is now clear that tumor cells possess a seemingly limitless capacity to evade cell death pathway activation, maintain essential survival programming, and initiate resistance networks that block efficacy of cytotoxic and targeted therapy. Given this amazing survival capability, how then to design approaches for effective eradication of malignant cells Also present within all solid tumors is a diverse assemblage of genomically stable immune cell types. Whereas some of these possess documented activities that foster tumor progression, others possess inherent activities that when favored lead to rapid tumor cell elimination. This review focuses on aspects of dendritic cell biology in solid tumors, especially breast cancers, which point to dendritic cells as a tractable tool to exploit for immune-based therapies.

KW - h

KW - Cancer

KW - Dendritic Cells

KW - Immunogenic Cell Death

KW - Inflammation

UR - http://www.scopus.com/inward/record.url?scp=84889048897&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84889048897&partnerID=8YFLogxK

U2 - 10.1097/PPO.0000000000000007

DO - 10.1097/PPO.0000000000000007

M3 - Article

C2 - 24270350

AN - SCOPUS:84889048897

VL - 19

SP - 511

EP - 516

JO - Cancer journal (Sudbury, Mass.)

JF - Cancer journal (Sudbury, Mass.)

SN - 1528-9117

IS - 6

ER -